HASBROUCK HEIGHTS, N.J., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that the Company will be presenting at the Singular Research Annual "Best of the Uncovereds" Conference in Los Angeles November 4, 2010.

Paul Averback, Nymox's CEO, will present at the conference. During the remainder of the day, Dr. Averback will meet with investors during a series of one-on-one breakout meetings at the conference.

The conference is being held Thursday at the Luxe Sunset Boulevard Hotel in Los Angeles.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new NX-1207 drug for benign prostatic hyperplasia (BPH) is in Phase 3 development in the U.S., and has potential use in other clinical indications. The Company has other drugs in development, and offers NicAlert TM and TobacAlert TM tests for measuring tobacco product exposure, and AlzheimAlert TM, a test to aid in the diagnosis of Alzheimer's disease.

About Singular Research

Singular Research aims to be the most trusted supplier of independent research on small-cap companies. * Our analysts research companies generally that are not covered by any other firms. * We provide Honest Advice: Our Independent analysts have no financial interest in the stocks we cover. Analysts are compensated based on the accuracy of their research calls not through trading commissions or investment banking fees * Track Record: Our coverage list compounded annual performance since inception is 13.04% vs. 3.45% for the Russell 2000, from August 2004 through September 2010. Performance YTD in 2010 is 8.9% vs. 7.4% for the Russell 2000. http://www.singular-research.com/discover/broadcast-news.htm

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT:  Nymox Pharmaceutical Corporation          Roy Wolvin          1-800-936-9669          info@nymox.com          Singular Research          Robert Maltbie, Jr., CFA          818-222-6915          robert@singularresearch.com